Adaptive Phage Therapeutics

Adaptive Phage Therapeutics (APT) is a biotechnology startup founded in 2016 with the mission of providing safe, rapidly deployable, and cost-effective cures for bacterial infections. APT's PhageBank™ approach harnesses a diverse library of bacteriophages, offering broad spectrum and polymicrobial coverage to combat the challenge of antimicrobial resistance (AMR). The company has commercialized a proprietary phage susceptibility assay in partnership with Mayo Clinic Laboratories to match phages. Originally developed by the U.S. Department of Defense's biodefense program, APT acquired the global commercial rights in 2017. In June 2023, APT secured a $12.00M Series B investment led by Deerfield Capital Management and the AMR Action Fund. Under an FDA emergency Investigational New Drug allowance, APT has administered investigational PhageBank™ therapy to over 40 critically ill patients